OmniAb, Inc. Common Stock OABI
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T03:16:41.957Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-04-16
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:01.02601767Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T03:16:39.390920+00:00
OmniAb, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 3.48 | 177.1% | 52.2% | |||
| 25Δ | 4.02 | 153.0% | 43.4% | |||
| 30Δ | 4.56 | 128.8% | 34.6% | |||
| 35Δ | 5.07 | 108.5% | 26.8% | |||
| 40Δ | 5.46 | 104.1% | 23.6% | |||
| 45Δ | 6.39 | 84.0% | 41.1% | 5.84 | 99.8% | 20.4% |
| 50Δ | 6.05 | 87.9% | 37.1% | 6.23 | 95.4% | 17.1% |
| 55Δ | 5.70 | 91.8% | 33.1% | 6.61 | 91.1% | 13.9% |
| 60Δ | 5.35 | 95.7% | 29.0% | 6.99 | 86.7% | 10.7% |
| 65Δ | 5.00 | 99.6% | 25.0% | 7.38 | 82.4% | 7.4% |
| 70Δ | 4.49 | 108.2% | 21.6% | 8.07 | 82.0% | 5.1% |
| 75Δ | 3.98 | 116.9% | 18.2% | 8.92 | 83.5% | 3.3% |
| 80Δ | 3.47 | 125.6% | 14.8% | 9.76 | 85.1% | 1.5% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.48
- IV
- 177.1%
- B/E move
- 52.2%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.02
- IV
- 153.0%
- B/E move
- 43.4%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.56
- IV
- 128.8%
- B/E move
- 34.6%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.07
- IV
- 108.5%
- B/E move
- 26.8%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.46
- IV
- 104.1%
- B/E move
- 23.6%
45Δ
- Pseudo strike
- 6.39
- IV
- 84.0%
- B/E move
- 41.1%
- Pseudo strike
- 5.84
- IV
- 99.8%
- B/E move
- 20.4%
50Δ
- Pseudo strike
- 6.05
- IV
- 87.9%
- B/E move
- 37.1%
- Pseudo strike
- 6.23
- IV
- 95.4%
- B/E move
- 17.1%
55Δ
- Pseudo strike
- 5.70
- IV
- 91.8%
- B/E move
- 33.1%
- Pseudo strike
- 6.61
- IV
- 91.1%
- B/E move
- 13.9%
60Δ
- Pseudo strike
- 5.35
- IV
- 95.7%
- B/E move
- 29.0%
- Pseudo strike
- 6.99
- IV
- 86.7%
- B/E move
- 10.7%
65Δ
- Pseudo strike
- 5.00
- IV
- 99.6%
- B/E move
- 25.0%
- Pseudo strike
- 7.38
- IV
- 82.4%
- B/E move
- 7.4%
70Δ
- Pseudo strike
- 4.49
- IV
- 108.2%
- B/E move
- 21.6%
- Pseudo strike
- 8.07
- IV
- 82.0%
- B/E move
- 5.1%
75Δ
- Pseudo strike
- 3.98
- IV
- 116.9%
- B/E move
- 18.2%
- Pseudo strike
- 8.92
- IV
- 83.5%
- B/E move
- 3.3%
80Δ
- Pseudo strike
- 3.47
- IV
- 125.6%
- B/E move
- 14.8%
- Pseudo strike
- 9.76
- IV
- 85.1%
- B/E move
- 1.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 106.21% | |
| 120.35% | |
| 113.58% |
Biotechnology
OBIO
Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases. The company is headquartered in New…
More →OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern,…
More →OCS
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug,…
More →OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its…
More →OLMA
Description unavailable
More →OMER
Description unavailable
More →